N@N

Uy Ear Reiterated (ACAD) at Hold and Held Target at $19 on, Mar 13th, 2023

Uy Ear of Mizuho, Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Hold and Held Target at $19 on, Mar 13th, 2023.

Uy has made no other calls on ACAD in the last 4 months.

There are 8 other peers that have a rating on ACAD. Out of the 8 peers that are also analyzing ACAD, 5 agree with Uy's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $20 on, Wednesday, March 1st, 2023
• Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $19 on, Tuesday, February 28th, 2023
• Neena Bitritto-Garg of "Citigroup" Maintained at Hold and Held Target at $19 on, Tuesday, February 28th, 2023
• Jason West of "JMP Securities" Maintained at Hold with Decreased Target to $22 on, Tuesday, February 28th, 2023
• Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022

These are the ratings of the 3 analyists that currently disagree with Uy

---

• Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $25 on, Tuesday, February 28th, 2023
• Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $27 on, Tuesday, February 28th, 2023
• Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023

Contributing Sources

---